|
|
|
Corporate Profile: Actinium Pharmaceuticals
| Summary: |
Actinium Pharmaceuticals is focused on the research, development and commercialization of the alpha emitting isotopes bismuth 213 (Bi-213) and actinium 225 (Ac-225) for fighting cancer and other cellular diseases.
|
| Address (HQ): |
501 Fifth Avenue
New York, NY 10017 |
| Phone #'s (HQ): |
| Main |
(646) 459-4201 |
| Human
Resources |
not known |
| Investor
Relations |
not known |
| Fax #'s (HQ): |
| Main |
not known |
| Human
Resources |
not known |
| Investor
Relations |
not known |
| Financial
information: |
| ATNM |
| Issued United States patents: |
| Issued U.S. patents: 1976-present: patent
link. |
| Filed United States patent applications: |
| Filed U.S. patent applications: 2001-present: patent
link. |
| Publications on PubMed: |
| Scientific publications on PubMed with an author from the company: publications
link. |
|
|
|
